CoChat

Photodynamic Therapy for Thyroid Cancer

Open access
Inglot, Julia, Strzelczyk, Joanna Katarzyna, Bartusik-Aebisher, Dorota, Aebisher, David · 2025 · BioMed

The DOI matches its Crossref record; 64 of the 67 references it cites were found in a registry or an index; 57 of the 142 sources its claims cite were checked for support.

Abstract

Background/Objectives: Thyroid cancer is the most common cancer of the endocrine system worldwide. Despite many available therapeutic options, the mortality rate of some subtypes, including anaplastic thyroid cancer, is still significant. Photodynamic therapy brings hope, which, through local activation of cell death pathways, as well as its effect on the immune system and vessels feeding the tumor, brings effects incomparable to classical methods. Photosensitizers particularly used in the case of thyroid cancer are hypericin, porphyrin, photophrin, radachlorin, or 5-aminolevulinic acid. Even better effects are achieved by administering sulforaphene, carboplatin, or genistein before therapy. Methods: For this research, we review articles in regard to provide a critical summary of the existing literature on thyroid cancer to explain the current state of scientific evidence on this topic. Conclusions: Photodynamic therapy is undoubtedly a technique of the future; the main advantages of which are low invasiveness, the possibility of combining with other treatment methods, or the possibility of outpatient use.

Overview

CoChat Summary

TL;DR

This narrative review summarizes the existing literature on thyroid cancer and the preclinical evidence for photodynamic therapy (PDT), concluding that PDT is a promising, minimally invasive approach whose use in thyroid cancer still requires further validation and standardization. The most studied photosensitizers are hypericin, porphyrin, photophrin, radachlorin, and 5-aminolevulinic acid, with enhanced effects when combined with sulforaphene, carboplatin, or genistein.

Key findings

  • PDT with hypericin (HYP) reduced viability of anaplastic thyroid cancer cell lines in a concentration-dependent manner (most pronounced up to 10 µg/ml), increased intracellular ROS, decreased mitochondrial membrane potential, and almost completely reduced tumor weight and volume in mice; HYP's absorption peak was 593 nm.
  • Porphyrin-HDL nanoparticle (PLP)-PDT (671 nm, 10 J/cm²) produced significant tumor cell apoptosis versus control (75.7% vs. 10.6% by TUNEL) in mouse and rabbit models, with preserved recurrent laryngeal nerve structure and no tumor cells on histology after day 53 in rabbits.
  • 5-ALA PDT with a 633 nm diode laser reduced tumor size in undifferentiated thyroid cancer, with tumor growth delay of approximately 48% at 7 days, 55% at 14 days, and 51% at 21 days; tumor necrosis occurred in 20% of mice.
  • Combining PDT with chemotherapy outperformed monotherapy: radachlorin-PDT plus carboplatin reduced live anaplastic cells to about 30% versus about 89% for carboplatin alone and about 80% for PDT alone, with complete inhibition at 0.05 mg/ml carboplatin plus 3.12 ng/ml radachlorin; ROS-positive cells were 81.6% with PDT versus 87.1% with combination, and mitochondrial membrane potential decreased 14.5% (carboplatin), 49.3% (PDT), and 80.6% (combination).

Methods

  • Design: narrative literature review summarizing current information on thyroid cancer (incidence, genetics, histopathology, diagnosis, treatment) and PDT.
  • Data sources: PubMed and Google Scholar databases; no systematic search strategy, inclusion criteria, or date range is reported.
  • Content synthesis: descriptive summary of preclinical in vitro and animal studies of PDT in thyroid cancer, organized by photosensitizer and by enhancing agent.

Limitations

  • Stated by the paper: "There are limited studies available on the use of PDT in the treatment of thyroid lesions"; PDT "requires further studies to validate and standardize its use"; the paper also notes a lack of specific standards and quality control for PDT.
  • Evident from the text: this is a preprint explicitly marked "Not peer-reviewed version," and the review reports no systematic search protocol, risk-of-bias assessment, or quantitative synthesis; the cited evidence is predominantly preclinical (cell lines and animal models), with no clinical trials of PDT in thyroid cancer described.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biomed5010008

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

28 Valid · 20 Not valid · 60 Not checked · 2 Own results and interpretations

66 more claims · 31 with their cited sources checked

Create a free account to see all 110 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 38
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 64 references

Cited by

Metadata

Authors
Inglot, J., Strzelczyk, J. K., Bartusik-Aebisher, D., & Aebisher, D.
Affiliations
  • University of Rzeszów (PL)
  • Medical University of Silesia (PL)
  • Department of Biochemistry and General Chemistry, Medical College, The Rzeszów University, 35-310 Rzeszów, Poland
Venue
BioMed
Publisher
MDPI AG
Published
2025-03-14
Volume
5
Issue
1
Pages
8
ISSN
2673-8430 (ISSN-L)
OpenAlex
W4408522540
Cited by
2
References
67
Citations by year
2026: 2
FWCI
1.32
Type
journal article
Language
en
Open access
Locations
  • BioMed (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
photodynamic therapy, thyroid cancer, anaplastic thyroid carcinoma, photosensitizers, hypericin, porphyrins, Radachlorin, 5-aminolevulinic acid, sulforaphene, carboplatin, genistein, tumor angiogenesis, combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Photodynamic Therapy for Thyroid Cancer. https://app.cochat.ai/papers/10.3390/biomed5010008
The paper
Inglot, J., Strzelczyk, J. K., Bartusik-Aebisher, D., & Aebisher, D. (2025). Photodynamic Therapy for Thyroid Cancer. BioMed. https://doi.org/10.3390/biomed5010008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.